Icelander chemical industry news

• 

  11 March 2026

  Elkem Restructures and Cuts Costs to Boost Competitiveness

  Elkem introduces a new structure, reduces workforce by 300, and cuts costs by NOK 1.9 billion to enhance profitability amid market challenges.
• 

  4 February 2026

  Kemira Enters Finland's Top 5 in Nordic Diversity Index

  Kemira improved its diversity ranking, focusing on gender, age, nationality, and education. The 2026 report highlights AI's role in digital leadership.
• 

  7 January 2026

  Grupa Azoty Secures Multi-Year Fertiliser Deal in Scandinavia

  The contract enhances export strategy, ensuring stable fertiliser supply to Scandinavia, meeting high standards and boosting sales in a key market.
• 

  12 December 2025

  Merck's WINREVAIR™ Gains EU CHMP Support for Broader PAH Use

  EU CHMP backs expanded WINREVAIR™ use for PAH, covering WHO FC II-IV. Decision by European Commission expected Q1 2026.
• 

  19 November 2025

  Merck's KEYTRUDA® Subcutaneous Form Approved by European Commission

  KEYTRUDA SC, a subcutaneous immune checkpoint inhibitor, is approved in Europe for faster administration across all adult indications.
• 

  18 November 2025

  EU Imposes Safeguard Measures on Ferroalloy Imports; Impact on Elkem

  The EU enacts tariff rate quotas on ferroalloy imports, effective Nov 2025 for three years, excluding silicon metal. Elkem anticipates sales shifts and potential price increases.

• 

  23 October 2025

  Elkem Q3 2025: Strong Operations and Cost Improvements Boost Results

  EBITDA fell 33% YoY due to low sales prices. Silicones division under review for sale. EU and US trade measures may impact future performance.
• 

  20 October 2025

  Elkem Reduces Ferrosilicon Output in Norway and Iceland

  Production cut due to weak European market and EU import investigation. Temporary layoffs possible. Aims to lower inventory and stabilize market.
• 

  19 September 2025

  Merck's ENFLONSIA™ Recommended by EU CHMP for RSV Prevention in Infants

  ENFLONSIA™ awaits EU approval for infant RSV prevention, offering a single-dose option for all weights. Backed by Phase 2b/3 and Phase 3 trials, decision expected by year-end.
• 

  19 September 2025

  Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use

  CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.